This pharmaceutical company has seen no estimate revision over the past 30 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if Friday’s rally can turn into more strength down the road.
Relypsa currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Medical Drug industry may consider better-ranked stocks like Akorn Inc. (AKRX), Mallinckrodt plc (MNK) and KaloBios Pharmaceuticals, Inc. (KBIO). While Akorn and Mallinckrodt sport a Zacks Rank #1 (Strong Buy), KaloBios bears a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment